Jordan-based Hikma Pharmaceuticals has signed a $112m agreement to acquire US-based Baxter Healthcare Corporation’s US generic injectables business. The multi source injectables business comprises a comprehensive and complementary portfolio of 41 products in over 150 dosage strengths and forms across 23 therapeutic areas.